摘要
目的:对比阿立哌唑口腔崩解片合并奥氮平与单用奥氮平治疗精神分裂症患者的疗效及安全性。方法:将符合入组标准的70例精神分裂症患者随机分为研究组(奥氮平合并阿立哌唑口腔崩解片治疗)和对照组(单用奥氮平治疗),观察6周。共完成研究62例,研究组30例,对照组32例,采用阳性与阴性症状量表(PANSS)分别评定基线和治疗后组内组间总分、各分量表分的变化以及不良反应。结果:研究组和对照组治疗后阳性量表分(t=13.081,13.239)、阴性量表分(t=28.492,25.533)、一般精神病理量表分(t=8.769,8.310)及总分(t=20.494,17.169)均较治疗前显著降低(P均<0.001);以研究组阴性量表分较对照组降分更显著(t=3.191,P<0.01)。两组不良反应发生率无统计学意义(χ2=0.21,P=0.647)。结论:奥氮平合并阿立哌唑口腔崩解片能明显地改善精神分裂症患者的阴性症状,同时不增加不良反应。
Objective：To compare the efficacy and safety of aripiprazole orally disintegrating tablets in combination with olanzapine and olanzapine alone in treatment of schizophrenia.Method：70 subjects meeting the inclusion criteria of schizophrenia patients were randomly divided into study group and control group,and 62 subjects completed the study.The study group（combining aripiprazole orally disintegrating tablets with olanzapine）consisted of 30 patients,and the control group（olanzapine alone） consisted of 32 patients.The study group was compared with the control group of changes of positive and negative symptoms scale（PANSS） total score and each subscale score and adverse reaction at baseline and after 6 weeks.Results：The two groups after treatment were significantly lower than before treatment in positive symptoms subscale scores（t=13.081,13.239）,negative symptoms subscale scores（t=28.492,25.533）,general psychiatric subscale scores（t=8.769,8.310） and total scores（t=20.494,17.169,all P0.001）.Negative symptoms subscale scores of the study group points were decreased significantly than that of the control group（t=3.191,P0.01）.The two groups were no difference in adverse events（χ2=0.21,P=0.647）.Conclusion：The combination of aripiprazole orally disintegrating tablets with olanzapine improved negative symptoms significantly,without adverse events increasing.
出处
《临床精神医学杂志》
2012年第6期411-412,共2页
Journal of Clinical Psychiatry
关键词
阿立哌唑口腔崩解片
奥氮平
精神分裂症
aripiprazole orally disintegrating tablets
olanzapine
schizophrenia
